Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) Operating Margin (2020 - 2022)

Candel Therapeutics' Operating Margin history spans 3 years, with the latest figure at 26132.26% for Q4 2022.

  • On a quarterly basis, Operating Margin rose 10286774.0% to 26132.26% in Q4 2022 year-over-year; TTM through Dec 2022 was 28000.81%, a 201394.0% decrease, with the full-year FY2022 number at 27777.6%, down 205160.0% from a year prior.
  • Operating Margin hit 26132.26% in Q4 2022 for Candel Therapeutics, up from 28648.39% in the prior quarter.
  • Over the last five years, Operating Margin for CADL hit a ceiling of 8448.39% in Q2 2020 and a floor of 129000.0% in Q4 2021.
  • Historically, Operating Margin has averaged 30554.55% across 3 years, with a median of 25900.0% in 2021.
  • Biggest five-year swings in Operating Margin: plummeted -10924194bps in 2021 and later soared 10286774bps in 2022.
  • Tracing CADL's Operating Margin over 3 years: stood at 19758.06% in 2020, then plummeted by -553bps to 129000.0% in 2021, then surged by 80bps to 26132.26% in 2022.
  • Business Quant data shows Operating Margin for CADL at 26132.26% in Q4 2022, 28648.39% in Q3 2022, and 28235.48% in Q2 2022.